Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis
Frontiers in Cellular and Infection Microbiology · 01.07.2026 · 16
DOI: 10.3389/fcimb.2026.1881444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 01.07.2026. Verfasst von Monika Kozińska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Fluoroquinolones, Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
Background
Fluoroquinolones (FQs) are a cornerstone of modern multidrug-resistant tuberculosis (MDR-TB) treatment, particularly within the WHO-recommended all-oral BPaLM regimen. The emergence of FQ-resistant Mycobacterium tuberculosis (MTB) poses a critical threat to these life-saving therapies. While the global proportion of FQ resistance among MDR/RR-TB cases is estimated at 19%, phenotypic and molecular data from low-incidence countries in Central and Eastern Europe remain limited. This study aimed to comprehensively assess the FQ resistance profile of MDR/RR-TB strains isolated in Poland between 2022 and 2024.
Methods
We analyzed 240 drug-resistant MTB isolates (228 MDR and 12 rifampicin-resistant) collected nationwide. Phenotypic drug susceptibility testing (DST) was performed using the Bactec MGIT 960 system. Isolates demonstrating resistance to levofloxacin and/or moxifloxacin ( n = 104) were further analyzed using Deeplex-Myc TB targeted next-generation sequencing (tNGS) to identify mutations within the quinolone resistance-determining region (QRDR) and determine strain spoligotypes.
Results
Phenotypic FQ resistance was detected in an alarming 43.0% (104/240) of isolates. Mutational analysis revealed eight variants in the gyrA gene and two variants in the gyrB gene. The most frequent mutations were D94G (44.2%), D94N (18.3%), and D94A (12.5%). Genome sequencing allowed the identification of 11 molecular families (spoligotypes), with the Beijing genotype being by far the dominant one and accounting for 91.0% of all isolates.
Conclusions
Our findings demonstrate a substantial and concerning burden of FQ resistance among MDR-TB strains in Poland, significantly exceeding global averages. The high prevalence of QRDR mutations and the dominance of the Beijing genotype highlight the urgent need for systematic molecular surveillance and rapid NGS-based diagnostics. Such measures are essential to ensure the effectiveness of the BPaLM regimen and prevent the further spread of highly drug-resistant TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.
- Laboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Kozińska, M., Głogowska, A., Minias, A., Dziadek, J., & Augustynowicz-Kopeć, E. (2026). Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1881444
Vancouver
Kozińska M, Głogowska A, Minias A, Dziadek J, Augustynowicz-Kopeć E. Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1881444
BibTeX
@article{Koziska2026,
author = {Kozińska, Monika and Głogowska, Agnieszka and Minias, Alina and Dziadek, Jarosław and Augustynowicz-Kopeć, Ewa},
title = {Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1881444}
}
EUVIMED